Results 1 to 10 of about 9,592 (241)

Hepatoprotective drug screening identifies daclatasvir, a promising therapeutic candidate for MASLD by targeting PLIN2 [PDF]

Journal of Lipid Research
Metabolic dysfunction-associated steatohepatitis (MASH) has become a global health challenge with limited therapeutic strategy. Here, this study aims to identify promising drug candidates for MASH and clarify its pharmacological mechanism.
Rui Shu, Song Tian, Weiyi Qu, Jinjie Yang, Wei Shi, Xinyan Li, Toujun Zou, Changjin Jiang, Yuxuan Zhang, Zifeng Yang, Han Tian, Hailong Yang, Jiajun Fu, Zhi-Gang She, Hongliang Li, Xiao-Jing Zhang   +15 more
doaj   +2 more sources

Prescription and efficacy of daclatasvir and sofosbuvir ± ribavirin for hepatitis C infection, including patient-reported outcomes, in routine practice in three European countries: The CMPASS-EU cohort study [PDF]

Cogent Medicine, 2020
Prescription and efficacy of daclatasvir and sofosbuvir ± ribavirin, including patient-reported outcomes, in routine practice in three European countries: the CMPASS-EU cohort study. Objectives: To identify patient characteristics associated with routine
Stefan Bourgeois, Karel van Erpecum, Jean Delwaide, Uwe Naumann, Stefan Christensen, Christophe Moreno, Anita Pathil, Emile Schippers, Nancy van Emmerik, Benoit Caritey, Conrad Fischer, Florence Mercier, Joerg Petersen   +12 more
doaj   +2 more sources

Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis [PDF]

, 2015
Importance Effective and well-tolerated, interferon-free regimens are needed for treatment of patients with chronic hepatitis C virus (HCV) infection and cirrhosis.
Cooper, James, Dore, Gregory J., Everson, Gregory, Freilich, Bradley, Ghesquiere, Wayne, Herring, Robert, Hughes, Eric A., Hézode, Christophe, Kwo, Paul, Lalezari, Jacob, McPhee, Fiona, Muir, Andrew J., Pockros, Paul J., Poordad, Fred, Ramji, Alnoor, Reau, Nancy, Sheikh, Aasim, Stuart, Katherine, Swenson, E. Scott, Thompson, Alexander J., Tran, Albert, Vierling, John, Yang, Rong, Yin, Philip D., Yozviak, Joseph   +24 more
core   +3 more sources

The Effectiveness of a Sofosbuvir/Daclatasvir Combination in the Treatment of HCV Infection in Patients from Mauritania Undergoing Chronic Hemodialysis [PDF]

Medicina
Background and Objectives: Hepatitis C virus (HCV) infection is highly prevalent among patients undergoing chronic hemodialysis in emerging countries and is associated with significant morbidity and mortality in this population.
Sidi Mohamed Mah, Soufiane Sid’Ahmed, Mohamed Lemrabott, Delahi Welli, Jemal Awa, Abdellatif Sidi Aly, Lionel Rostaing   +6 more
doaj   +2 more sources

Repurposing daclatasvir for MASLD Therapy—A promising step forward with challenges ahead [PDF]

Journal of Lipid Research
The article discusses the potential of repurposing daclatasvir, an FDA-approved anti-HCV drug, for treating metabolic dysfunction-associated steatotic liver disease (MASLD) and its advanced form, metabolic dysfunction-associated steatohepatitis (MASH ...
Carlos Jose Pirola
doaj   +2 more sources

A mini-review on sofosbuvir and daclatasvir treatment in coronavirus disease 2019

New Microbes and New Infections, 2021
Sofosbuvir and daclatasvir have been used successfully since 2013 for hepatitis C treatment. It has been shown by different studies that sofosbuvir can inhibit RNA polymerase of other positive-strand RNA viruses including Flaviviridae and Togaviridae ...
M. Shabani, B. Sadegh Ehdaei, F. Fathi, R. Dowran   +3 more
exaly   +3 more sources

Efficacy and safety of sofosbuvir plus daclatasvir in hemodialysis patients with genotype 1b or 2a hepatitis C virus infection: a single-arm, prospective real-world study [PDF]

Frontiers in Medicine
Background/aimsThis investigation assessed the clinical outcomes and adverse effects of combination therapy using sofosbuvir (SOF) and daclatasvir (DCV) among dialysis-dependent patients infected with hepatitis C virus (HCV) genotypes 1b or 2a in real ...
Kaili Wang, Hongyu Yao, Xia Zhou, Hongling Liu, Jun Zhao   +4 more
doaj   +2 more sources

Daclatasvir

Annals of Pharmacotherapy, 2016
Michael A Smith, rima mohammad
exaly   +4 more sources

Newly Proposed Dose of Daclatasvir to Prevent Lethal SARS-CoV-2 Infection in Human Transgenic ACE-2 Mice. [PDF]

Viruses
Mattos M, Sacramento CQ, Ferreira AC, Fintelman-Rodrigues N, Pereira-Dutra FS, de Freitas CS, Gesto JSM, Temerozo JR, Silva APDD, Moreira MTG, Silva RSC, Silveira GPE, Pinto DP, Pereira HM, Fonseca LB, Alves Ferreira M, Blanco C, Viola JPB, Bou-Habib DC, Bozza PT, Souza TML.   +20 more
europepmc   +2 more sources

The effect of OCT-2 inhibitor Daclatasvir on Metformin pharmacokinetics and pharmacodynamics at two dose levels: A Bayesian approach using Markov-Chain Monte Carlo simulations

Archives of Pharmaceutical Sciences Ain Shams University, 2022
Renal Organic Cation Transporter 2 (OCT2) plays a major role in metformin elimination. Daclatasvir, a Direct-Acting Antiviral (DAA), is an OCT2 inhibitor.
Mohamed Raslan, Lamia Elwakeel, Sara Shahin   +2 more
doaj   +1 more source